Cor Therapeutics, Inc. announces status of European regulatory filing.SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BUSINESS WIRE)--April 11, 1997-- COR Therapeutics, Inc. (Nasdaq: CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) today announced that the application for European marketing approval of INTEGRILIN(TM) (antithrombotic injection) as an adjunct therapy to prevent acute cardiac ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic complications in patients undergoing percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty n. Abbr. PTCA A procedure for enlarging a narrowed arterial lumen by peripheral introduction of a balloon-tip catheter followed by dilation of the lumen as the inflated catheter tip is (PTCA PTCA abbr. percutaneous transluminal coronary angioplasty PTCA Percutaneous transluminal coronary angioplasty, see there ) was withdrawn based on discussions with European regulatory authorities and Schering-Plough Corporation, COR's worldwide partner for the INTEGRILIN(TM) product. Additional INTEGRILIN(TM) clinical results are expected to be available later this year from PURSUIT, a 10,900 patient Phase III trial of INTEGRILIN(TM) for use in unstable angina and non-Q wave myocardial infarction. These results could form the basis for an application for marketing approval of INTEGRILIN(TM). The PTCA application was submitted last year by Schering-Plough to the European Agency for the Evaluation of Medicinal Products, the central regulatory agency for several European countries, and was based on the results of the IMPACT II study announced in 1995. COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. COR has complementary product research and development programs that seek to address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· , deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. and restenosis. This press release contains forward-looking statements that are subject to risks and uncertainties that may cause the Company's actual results to differ materially. A full discussion of the Company's operations and financial condition, and specific factors that could cause the Company's actual performance to differ from current expectations, are discussed in the Company's SEC reports, including, but not limited to, the Company's Report on Form 10-K for the year ended December 31, 1996. CONTACT: COR Therapeutics, Inc. Burns McClellan, Inc. Laura A. Brege Lisa Burns (Investors) Jacquelyn A. Jeffries (212) 505-1919 (415) 244-6893 Mike Sinclair (Media) (415) 352-6262 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion